Nothing in the RNS to get too excited about. Open to correction as always but why would they highlight in vitro studies vs a, ß, and ? variants without info on d? Have they not tested SNG001 in vitro vs d?
Why would they be highlighting efficacy against viral infection in patients with asthma and COPD when what everyone wants to here about is efficacy vs Covid? Although I guess the answer to that one might be that they have proper studies vs asthma and COPD and are still awaiting the data on Covid.
Poorly phrased. This might be better The link in Xviolet’s post seems to say that that the rise in Covid hospital cases is largely because a higher proportion of those admitted to hospital for other reasons turn out to have Covid.
Xviolet's post looks like it says hospital admissions with Covid are going up, but that's just because a higher proportion of people who are admitted for other reasons turn out to have covid "SARS-CoV-2 has been an incidental finding in patients that were admitted to the hospital for another medical, surgical or obstetric reason."
@Cont said " the directors don't even want to commit buying shares in their own company" Why would they do that? they are going to award themselves a bunch of options. Their interests will be aligned with other shareholders.